All articles by
Janssen’s nipocalimab shows potential benefit in Phase 2 UNITY trial
The proof-of-concept trial showed that 54% of participants treated with nipocalimab met the primary endpoint of live birth at or after the gestational age of 32 weeks without intrauterine transfusions
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
Study did not meet the primary endpoint
Soliris recommended for approval in the EU by CHMP for children and adolescents with gMG
The first-in-class C5 inhibitor reduced disease severity and symptoms with sustained
improvements over 26 weeks in Phase III clinical trial
Clario, Sleepiz partner to integrate sleep and respiratory parameters into clinical trials
The partnership intends to generate new data endpoints via a patient-centric and unobtrusive monitoring approach with a focus on precise and longitudinal data points
Artilysin – A Groundbreaking “Green Pharma” Solution
Embracing the “green pharma” philosophy, Lysando’s Artilysin molecules effectively target resistant pathogens while minimizing environmental, wastewater, and food chain impact
Talaris Therapeutics to merge with Tourmaline Bio in all-stock transaction
The merged firm will concentrate on developing Tourmaline’s TOUR006 programme, an anti-IL-6 antibody to treat thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)
Bio-Techne to acquire Swiss spatial biology firm Lunaphore
Lunaphore’s spatial biology portfolio uses precision microfluidic technology to find hyperplex proteomic and transcriptomic biomarkers in tumours and other tissues at single-cell and subcellular resolution
Wound dressing FibDex to be clinically tested for treatment of superficial dermal burns
UPM Biomedicals’ innovative wound dressing FibDex is undergoing a clinical investigation of performance and safety in patients with superficial dermal burns. The clinical investigation will be conducted by the Burn Centre of Uppsala University Hospital, Sweden, and is estimated to be completed in the beginning of the year 2025.
PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES
The Sponsored Research Agreement will help advance antidepressant treatments for patients in need
Pieris says AstraZeneca stops trials of elarekibep in response to toxicology signal
AstraZeneca has discontinued and ceased dosing in the ongoing clinical studies of IL-4 receptor based on the lung findings from a non-clinical 13-week GLP toxicology study